The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Treatment With Avelumab in Resistant Ovarian Cancer

By: Alison Tewksbury
Posted: Monday, March 25, 2019

For women with progressive advanced ovarian cancer, especially disease that has become resistant to platinum-based chemotherapy, current treatment options are limited. Mary L. Disis, MD, of the University of Washington School of Medicine, Seattle, and colleagues published findings of a phase Ib study (JAVELIN Solid Tumor) in JAMA Oncology. “Avelumab demonstrated anti-tumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer,” concluded the researchers.

Patients who had advanced ovarian cancer and previously had received chemotherapy, including a platinum- based agent, were enrolled in the study. Of 125 women in the expansion cohort, 28 patients received avelumab as a fourth-line treatment, and 22 patients received avelumab as fifth-line treatment. Participants received avelumab every 2 weeks until disease progression, toxicity, or withdrawal from study.

A confirmed objective response was seen in 12 patients (9.6 %), with a complete response in 1 patient (0.8 %).The median progression-free survival was 2.6 months, and 10.2 % of patients saw a progression-free survival of 1 year. The median overall survival was 11.2 months. 

Adverse events included infusion-related reactions (20 %), fatigue (13.6 %), diarrhea (12.0 %), and nausea (11.2 %). Grade 3 or higher adverse events occurred in 7.2 % of patients, and 16.8 % of patients experienced an immune-related adverse event of any grade.

Although this study demonstrates the potential of avelumab as a monotherapy, further studies are underway to determine whether greater efficacy can be achieved by using avelumab in combination with chemotherapy.

Disclosure: The study authors’ disclosures can be found at jamanetwork.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.